Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers

•Immune-induced vaccination has been suggested as a key global strategy for SARS-CoV-2.•Previous-natural infection subjects presented higher value of antibodies after 12 days.•Antibodies levels did not differ between males and females.•Antibodies levels were lower in subjects older than 60 years aft...

Full description

Saved in:
Bibliographic Details
Published inClinica chimica acta Vol. 519; pp. 60 - 63
Main Authors Padoan, Andrea, Dall'Olmo, Luigi, Rocca, Foscarina della, Barbaro, Francesco, Cosma, Chiara, Basso, Daniela, Cattelan, Annamaria, Cianci, Vito, Plebani, Mario
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.08.2021
Subjects
Online AccessGet full text
ISSN0009-8981
1873-3492
1873-3492
DOI10.1016/j.cca.2021.04.006

Cover

Abstract •Immune-induced vaccination has been suggested as a key global strategy for SARS-CoV-2.•Previous-natural infection subjects presented higher value of antibodies after 12 days.•Antibodies levels did not differ between males and females.•Antibodies levels were lower in subjects older than 60 years after 12 days, not at 28 days. Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is needed. 163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively. Significant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28. Our study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant.
AbstractList Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is needed. 163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively. Significant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28. Our study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant.
•Immune-induced vaccination has been suggested as a key global strategy for SARS-CoV-2.•Previous-natural infection subjects presented higher value of antibodies after 12 days.•Antibodies levels did not differ between males and females.•Antibodies levels were lower in subjects older than 60 years after 12 days, not at 28 days. Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is needed. 163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively. Significant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28. Our study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant.
Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is needed.BACKGROUNDVaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several COVID-19 vaccines is now a global health-care priority but more information about humoral responses to single- and double-dose vaccine is needed.163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively.METHODS163 health care workers (HCW) of the Padua University Hospitals, who underwent a complete vaccination campaign with BNT162b2 vaccine were asked to collect serum samples at 12 (t12) and 28 (t28) days after the first inoculum to allow the measurement of SARS-CoV-2 Antibodies (Ab) using chemiluminescent assays against the spike (S) protein and the Receptor Binding Domain (RBD) of the virus, respectively.Significant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28.RESULTSSignificant differences were found at t12 for infection-naïve and subjects with previous-natural infection who present higher values of specific antibodies, while no significant differences have been found between t12 and t28. No statistically significant difference was found between male and female, while lower Ab levels have been observed in subjects older than 60 years at t12 but not at t28.Our study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant.CONCLUSIONSOur study confirms observed differences in vaccine responses between infection-naïve and subjects with previous natural infection at t12 but not for a longer time. The influence of sex and age deserves further studies, even if the relationship with age seems particularly significant.
Author Cosma, Chiara
Cianci, Vito
Barbaro, Francesco
Dall'Olmo, Luigi
Basso, Daniela
Padoan, Andrea
Plebani, Mario
Cattelan, Annamaria
Rocca, Foscarina della
Author_xml – sequence: 1
  givenname: Andrea
  orcidid: 0000-0003-1284-7885
  surname: Padoan
  fullname: Padoan, Andrea
  organization: Department of Medicine-DIMED, University of Padova, Italy
– sequence: 2
  givenname: Luigi
  surname: Dall'Olmo
  fullname: Dall'Olmo, Luigi
  organization: Department of Surgical Oncological and Gastroenterological Sciences – DISCOG, University of Padova, Italy
– sequence: 3
  givenname: Foscarina della
  surname: Rocca
  fullname: Rocca, Foscarina della
  organization: Emergency Department, Padua University Hospital, Padua, Italy
– sequence: 4
  givenname: Francesco
  surname: Barbaro
  fullname: Barbaro, Francesco
  organization: Infective and Tropical Disease Unit, Padua University Hospital, Padua, Italy
– sequence: 5
  givenname: Chiara
  surname: Cosma
  fullname: Cosma, Chiara
  organization: Department of Laboratory Medicine, University-Hospital of Padova, Italy
– sequence: 6
  givenname: Daniela
  orcidid: 0000-0001-8745-6171
  surname: Basso
  fullname: Basso, Daniela
  organization: Department of Medicine-DIMED, University of Padova, Italy
– sequence: 7
  givenname: Annamaria
  surname: Cattelan
  fullname: Cattelan, Annamaria
  organization: Infective and Tropical Disease Unit, Padua University Hospital, Padua, Italy
– sequence: 8
  givenname: Vito
  surname: Cianci
  fullname: Cianci, Vito
  organization: Emergency Department, Padua University Hospital, Padua, Italy
– sequence: 9
  givenname: Mario
  orcidid: 0000-0002-0270-1711
  surname: Plebani
  fullname: Plebani, Mario
  email: mario.plebani@unipd.it
  organization: Department of Medicine-DIMED, University of Padova, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33857476$$D View this record in MEDLINE/PubMed
BookMark eNp9kctuFDEQRS0URCaBD2CDvGTTjd3uhy0kpBCFhxSRTbK23OVq2kOPPdieoOTr8WhCBCyysEp2nXvLqntCjnzwSMhrzmrOeP9uXQOYumENr1lbM9Y_IysuB1GJVjVHZMUYU5VUkh-Tk5TW5dqynr8gx0LIbmiHfkWmM5_dGOwdjZi2wSekOdDJxZSp8ZYmhFCKDaURJvrx2zXvm7GhzlNDIcwh5v07zCYayBjdPVo6o1nyDCYi_RXiD4zpJXk-mSXhq4d6Sm4-XVyff6kurz5_PT-7rKDjQ64En7iVyliOjWKjaadhlKNABWyyvZCDsYBGCQ7IjGyUaKwUYIRqOyhnEKfkw8F3uxs3WGCfo1n0NrqNiXc6GKf_7Xg36-_hVkvW9arlxeDtg0EMP3eYst64BLgsxmPYJd10vO2UZD0r6Ju_Zz0O-bPcAvADADGkFHF6RDjT-wD1WpcA9T5AzVpdAiya4T8NuGyyC_vvuuVJ5fuDEst-bx1GncChB7QuImRtg3tC_Rsq5LX7
CitedBy_id crossref_primary_10_3390_vaccines9060652
crossref_primary_10_1515_cclm_2022_0418
crossref_primary_10_3390_vaccines10060909
crossref_primary_10_1016_j_clinbiochem_2023_03_003
crossref_primary_10_3390_vaccines10122125
crossref_primary_10_3390_diseases13030078
crossref_primary_10_3389_fimmu_2023_1136308
crossref_primary_10_3390_vaccines9121377
crossref_primary_10_1515_cclm_2021_0687
crossref_primary_10_1002_jmv_27096
crossref_primary_10_3390_diagnostics11060941
crossref_primary_10_3389_fimmu_2021_779212
crossref_primary_10_3390_biomedicines11102661
crossref_primary_10_1186_s13027_021_00375_2
crossref_primary_10_3390_jcm12093172
crossref_primary_10_1080_22221751_2021_1953403
crossref_primary_10_3389_fimmu_2021_752233
crossref_primary_10_3390_vaccines11010051
crossref_primary_10_3390_vaccines10050734
crossref_primary_10_3390_microorganisms10091812
crossref_primary_10_3390_vaccines10010064
crossref_primary_10_1515_cclm_2022_0322
crossref_primary_10_3390_vaccines10091443
crossref_primary_10_1016_j_cca_2021_10_035
crossref_primary_10_3390_tropicalmed9030061
crossref_primary_10_3390_vaccines9111322
crossref_primary_10_1002_jmv_27420
crossref_primary_10_1016_j_vaccine_2021_11_081
crossref_primary_10_1515_cclm_2022_0170
crossref_primary_10_3390_diagnostics11091709
crossref_primary_10_1016_j_cca_2021_10_028
crossref_primary_10_1016_j_heliyon_2022_e09438
crossref_primary_10_3390_vaccines9101092
crossref_primary_10_1136_jclinpath_2021_207572
crossref_primary_10_1016_j_mayocp_2021_08_013
crossref_primary_10_1016_j_jiph_2023_06_014
crossref_primary_10_1016_j_celrep_2022_110336
crossref_primary_10_1016_j_heliyon_2023_e16547
crossref_primary_10_3390_vaccines10040531
crossref_primary_10_3390_vaccines10081169
crossref_primary_10_1515_cclm_2021_1247
crossref_primary_10_1186_s12879_024_09338_5
crossref_primary_10_3390_vaccines9060672
crossref_primary_10_1016_j_jcv_2021_105057
crossref_primary_10_1186_s12916_022_02297_1
crossref_primary_10_1515_labmed_2021_0156
crossref_primary_10_1016_j_jcvp_2022_100094
crossref_primary_10_1128_spectrum_01181_21
crossref_primary_10_1515_cclm_2023_0129
crossref_primary_10_3390_vaccines9111357
crossref_primary_10_1016_j_eclinm_2021_101253
crossref_primary_10_1186_s13027_022_00451_1
crossref_primary_10_1038_s41392_022_01007_w
crossref_primary_10_1515_cclm_2021_0703
crossref_primary_10_1016_j_cca_2022_02_014
crossref_primary_10_7759_cureus_45143
crossref_primary_10_1080_10408363_2022_2038539
crossref_primary_10_1080_23744235_2021_1974540
crossref_primary_10_1111_all_15007
crossref_primary_10_3390_vaccines11071183
crossref_primary_10_3390_vaccines9111223
crossref_primary_10_1016_j_molimm_2023_09_001
crossref_primary_10_3390_vaccines10030474
crossref_primary_10_1002_jmv_27688
crossref_primary_10_3390_jpm12060994
crossref_primary_10_2139_ssrn_4016384
Cites_doi 10.1016/j.cca.2020.05.050
10.1101/2021.02.23.21249481
10.1126/science.abb3221
10.1038/s41591-020-0913-5
10.1056/NEJMc2101667
10.1056/NEJMoa2035389
10.1515/cclm-2021-0023
10.1001/jama.2021.4388
10.3390/jcm9123989
10.1016/S0140-6736(21)00501-8
10.1056/NEJMoa2034577
10.1101/2021.03.10.21253260
10.1038/s41591-020-01179-4
10.1056/NEJMoa2028436
10.1056/NEJMoa2027906
10.1016/j.jcv.2021.104784
10.1016/j.ebiom.2020.103087
ContentType Journal Article
Copyright 2021 Elsevier B.V.
Copyright © 2021 Elsevier B.V. All rights reserved.
2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V.
Copyright_xml – notice: 2021 Elsevier B.V.
– notice: Copyright © 2021 Elsevier B.V. All rights reserved.
– notice: 2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V.
DBID AAYXX
CITATION
NPM
7X8
5PM
DOI 10.1016/j.cca.2021.04.006
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EISSN 1873-3492
EndPage 63
ExternalDocumentID PMC8056941
33857476
10_1016_j_cca_2021_04_006
S0009898121001297
Genre Journal Article
GroupedDBID ---
--K
--M
.55
.GJ
.~1
0R~
1B1
1RT
1~.
1~5
29B
4.4
457
4G.
53G
5GY
5VS
6J9
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AAXUO
ABBQC
ABFNM
ABFRF
ABGSF
ABJNI
ABLVK
ABMAC
ABMZM
ABUDA
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
ADMUD
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AHPSJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DOVZS
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
G8K
GBLVA
HLW
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
LCYCR
LX3
M41
MO0
N9A
O-L
O9-
OAUVE
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
RNS
ROL
RPZ
SBG
SDF
SDG
SDP
SES
SEW
SPCBC
SSH
SSU
SSZ
T5K
WH7
WUQ
X7M
XPP
ZA5
ZGI
~02
~G-
AATTM
AAXKI
AAYWO
AAYXX
ABDPE
ABWVN
ACIEU
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
CITATION
EFKBS
~HD
AGRNS
NPM
7X8
ACLOT
5PM
ID FETCH-LOGICAL-c517t-31f1d89ad1e290ba4f7b8b3e9c0fd6387adcea931ce0a82932d83ca3945c94573
IEDL.DBID AIKHN
ISSN 0009-8981
1873-3492
IngestDate Thu Aug 21 14:34:52 EDT 2025
Sun Sep 28 15:58:25 EDT 2025
Mon Jul 21 05:33:50 EDT 2025
Thu Sep 18 00:15:20 EDT 2025
Thu Apr 24 23:09:33 EDT 2025
Fri Feb 23 02:45:17 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19
BNT162b2
Immunological response
Antibody
SARS-CoV-2 vaccine
Serology
Immunoassays
Language English
License Copyright © 2021 Elsevier B.V. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c517t-31f1d89ad1e290ba4f7b8b3e9c0fd6387adcea931ce0a82932d83ca3945c94573
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-8745-6171
0000-0002-0270-1711
0000-0003-1284-7885
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8056941
PMID 33857476
PQID 2514598060
PQPubID 23479
PageCount 4
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8056941
proquest_miscellaneous_2514598060
pubmed_primary_33857476
crossref_primary_10_1016_j_cca_2021_04_006
crossref_citationtrail_10_1016_j_cca_2021_04_006
elsevier_sciencedirect_doi_10_1016_j_cca_2021_04_006
PublicationCentury 2000
PublicationDate 2021-08-01
PublicationDateYYYYMMDD 2021-08-01
PublicationDate_xml – month: 08
  year: 2021
  text: 2021-08-01
  day: 01
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Clinica chimica acta
PublicationTitleAlternate Clin Chim Acta
PublicationYear 2021
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Prendecki, Clarke, Brown, Cox, Gleeson, Guckian, Randell, Pria, Lightstone, Xu, Barclay, McAdoo, Kelleher, Willicombe (b0080) 2021; 6736
Plebani (b0060) 2020; 61
F. Krammer, K. Srivastava, H. Alshammary, A.A. Amoako, M.H. Awawda, K.F. Beach, M.C. Bermúdez-González, D.A. Bielak, J.M. Carreño, R.L. Chernet, L.Q. Eaker, E.D. Ferreri, D.L. Floda, C.R. Gleason, J.Z. Hamburger, K. Jiang, G. Kleiner, D. Jurczyszak, J.C. Matthews, W.A. Mendez, I. Nabeel, L.C.F. Mulder, A.J. Raskin, K.T. Russo, A.-B.T. Salimbangon, M. Saksena, A.S. Shin, G. Singh, L.A. Sominsky, D. Stadlbauer, A. Wajnberg, V. Simon, Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine, N. Engl. J. Med. (2021) NEJMc2101667.
Walsh, Frenck, Falsey, Kitchin, Absalon, Gurtman, Lockhart, Neuzil, Mulligan, Bailey, Swanson, Li, Koury, Kalina, Cooper, Fontes-Garfias, Shi, Türeci, Tompkins, Lyke, Raabe, Dormitzer, Jansen, Şahin, Gruber (b0025) 2020; 383
Edara, Hudson, Xie, Ahmed, Suthar (b0090) 2021
Baden, El Sahly, Essink, Kotloff, Frey, Novak, Diemert, Spector, Rouphael, Creech, McGettigan, Khetan, Segall, Solis, Brosz, Fierro, Schwartz, Neuzil, Corey, Gilbert, Janes, Follmann, Marovich, Mascola, Polakowski, Ledgerwood, Graham, Bennett, Pajon, Knightly, Leav, Deng, Zhou, Han, Ivarsson, Miller, Zaks (b0070) 2021; 384
F. Barbaro, F. Della Rocca, A. Padoan, A. Aita, V. Cianci, D. Basso, A. Cattelan, D. Donato, M. Plebani, L. Dall’Olmo, A longitudinal study of healthcare workers’ surveillance during the ongoing COVID-19 Epidemics in Italy: is SARS-CoV-2 still a threat for the Health-care System? MedRxiv (2021) 2021.02.23.21249481, doi: 10.1101/2021.02.23.21249481.
Poljak, Oštrbenk Valenčak, Štamol, Seme (b0050) 2021; 137
Polack, Thomas, Kitchin, Absalon, Gurtman, Lockhart, Perez, Pérez Marc, Moreira, Zerbini, Bailey, Swanson, Roychoudhury, Koury, Li, Kalina, Cooper, Frenck, Hammitt, Türeci, Nell, Schaefer, Ünal, Tresnan, Mather, Dormitzer, Şahin, Jansen, Gruber (b0005) 2020; 383
Plebani, Padoan, Negrini, Carpinteri, Sciacovelli (b0030) 2020; 509
Amanat, Stadlbauer, Strohmeier, Nguyen, Chromikova, McMahon, Jiang, Arunkumar, Jurczyszak, Polanco, Bermudez-Gonzalez, Kleiner, Aydillo, Miorin, Fierer, Lugo, Kojic, Stoever, Liu, Cunningham-Rundles, Felgner, Moran, García-Sastre, Caplivski, Cheng, Kedzierska, Vapalahti, Hepojoki, Simon, Krammer (b0035) 2020; 26
Schaffner, Risch, Aeschbacher, Risch, Weber, Thiel, Jüngert, Pichler, Grossmann, Wohlwend, Lung, Hillmann, Bigler, Bodmer, Imperiali, Renz, Kohler, Vernazza, Kahlert, Twerenbold, Paprotny, Conen, Risch (b0055) 2020; 9
C. Manisty, A.D. Otter, T.A. Treibel, ine McKnight, D.M. Altmann, T. Brooks, M. Noursadeghi, R.J. Boyton, A. Semper, J.C. Moon, Correspondence antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals, Lancet 6736 (2021) 2–3.
European center for disease prevention and control (ECDC), Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU / EEA and the UK Key findings, (2020) 1–22.
Anderson, Rouphael, Widge, Jackson, Roberts, Makhene, Chappell, Denison, Stevens, Pruijssers, McDermott, Flach, Lin, Doria-Rose, O’Dell, Schmidt, Corbett, Swanson, Padilla, Neuzil, Bennett, Leav, Makowski, Albert, Cross, Edara, Floyd, Suthar, Martinez, Baric, Buchanan, Luke, Phadke, Rostad, Ledgerwood, Graham, Beigel (b0015) 2020; 383
Li, Pei, Chen, Song, Zhang, Yang, Shaman (b0065) 2020; 368
F. Bonelli, F.A. Blocki, T. Bunnell, E. Chu, O.A. De La, D.G. Grenache, G. Marzucchi, E. Montomoli, L. Okoye, L. Pallavicini, V.A. Streva, A. Torelli, A. Wagner, D. Zanin, C. Zierold, J.J. Wassenberg, Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. Clin Chem Lab Med. 2021 [ahead of print], doi: 10.1515/cclm-2021-0023.
Barrett, Belij-Rammerstorfer, Dold, Ewer, Folegatti, Gilbride, Halkerston, Hill, Jenkin, Stockdale, Verheul, Aley, Angus, Bellamy, Berrie, Bibi, Bittaye, Carroll, Cavell, Clutterbuck, Edwards, Flaxman, Fuskova, Gorringe, Hallis, Kerridge, Lawrie, Linder, Liu, Madhavan, Makinson, Mellors, Minassian, Moore, Mujadidi, Plested, Poulton, Ramasamy, Robinson, Rollier, Song, Snape, Tarrant, Taylor, Thomas, Voysey, Watson, Wright, Douglas, Green, Hill, Lambe, Gilbert, Pollard (b0010) 2021; 27
A. Padoan, F. Bonfante, C. Cosma, C. Di Chiara, L. Sciacovelli, M. Pagliari, A. Bortolami, P. Costenaro, G. Musso, D. Basso, C. Giaquinto, M. Plebani, Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers, Clin. Chem. Lab. Med. (2021) (accepted for pubblication on April 1st, 2021).
10.1016/j.cca.2021.04.006_b0085
10.1016/j.cca.2021.04.006_b0020
10.1016/j.cca.2021.04.006_b0075
10.1016/j.cca.2021.04.006_b0045
Schaffner (10.1016/j.cca.2021.04.006_b0055) 2020; 9
Polack (10.1016/j.cca.2021.04.006_b0005) 2020; 383
Baden (10.1016/j.cca.2021.04.006_b0070) 2021; 384
Plebani (10.1016/j.cca.2021.04.006_b0060) 2020; 61
Edara (10.1016/j.cca.2021.04.006_b0090) 2021
Poljak (10.1016/j.cca.2021.04.006_b0050) 2021; 137
Prendecki (10.1016/j.cca.2021.04.006_b0080) 2021; 6736
Plebani (10.1016/j.cca.2021.04.006_b0030) 2020; 509
Barrett (10.1016/j.cca.2021.04.006_b0010) 2021; 27
Amanat (10.1016/j.cca.2021.04.006_b0035) 2020; 26
Li (10.1016/j.cca.2021.04.006_b0065) 2020; 368
Anderson (10.1016/j.cca.2021.04.006_b0015) 2020; 383
Walsh (10.1016/j.cca.2021.04.006_b0025) 2020; 383
10.1016/j.cca.2021.04.006_b0040
10.1016/j.cca.2021.04.006_b0095
References_xml – volume: 27
  start-page: 279
  year: 2021
  end-page: 288
  ident: b0010
  article-title: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
  publication-title: Nat. Med.
– volume: 509
  start-page: 1
  year: 2020
  end-page: 7
  ident: b0030
  article-title: Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays?
  publication-title: Clin. Chim. Acta.
– volume: 383
  start-page: 2427
  year: 2020
  end-page: 2438
  ident: b0015
  article-title: Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
  publication-title: N. Engl. J. Med.
– reference: European center for disease prevention and control (ECDC), Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU / EEA and the UK Key findings, (2020) 1–22.
– volume: 6736
  start-page: 10
  year: 2021
  end-page: 12
  ident: b0080
  article-title: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
  publication-title: Lancet
– volume: 137
  year: 2021
  ident: b0050
  article-title: Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain
  publication-title: J. Clin. Virol.
– reference: F. Bonelli, F.A. Blocki, T. Bunnell, E. Chu, O.A. De La, D.G. Grenache, G. Marzucchi, E. Montomoli, L. Okoye, L. Pallavicini, V.A. Streva, A. Torelli, A. Wagner, D. Zanin, C. Zierold, J.J. Wassenberg, Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. Clin Chem Lab Med. 2021 [ahead of print], doi: 10.1515/cclm-2021-0023.
– volume: 384
  start-page: 403
  year: 2021
  end-page: 416
  ident: b0070
  article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
  publication-title: N. Engl. J. Med.
– reference: F. Krammer, K. Srivastava, H. Alshammary, A.A. Amoako, M.H. Awawda, K.F. Beach, M.C. Bermúdez-González, D.A. Bielak, J.M. Carreño, R.L. Chernet, L.Q. Eaker, E.D. Ferreri, D.L. Floda, C.R. Gleason, J.Z. Hamburger, K. Jiang, G. Kleiner, D. Jurczyszak, J.C. Matthews, W.A. Mendez, I. Nabeel, L.C.F. Mulder, A.J. Raskin, K.T. Russo, A.-B.T. Salimbangon, M. Saksena, A.S. Shin, G. Singh, L.A. Sominsky, D. Stadlbauer, A. Wajnberg, V. Simon, Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine, N. Engl. J. Med. (2021) NEJMc2101667.
– volume: 26
  start-page: 1033
  year: 2020
  end-page: 1036
  ident: b0035
  article-title: A serological assay to detect SARS-CoV-2 seroconversion in humans
  publication-title: Nat. Med.
– year: 2021
  ident: b0090
  article-title: Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination
  publication-title: JAMA
– reference: C. Manisty, A.D. Otter, T.A. Treibel, ine McKnight, D.M. Altmann, T. Brooks, M. Noursadeghi, R.J. Boyton, A. Semper, J.C. Moon, Correspondence antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals, Lancet 6736 (2021) 2–3.
– volume: 368
  start-page: 489
  year: 2020
  end-page: 493
  ident: b0065
  article-title: Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)
  publication-title: Science (80)
– volume: 383
  start-page: 2603
  year: 2020
  end-page: 2615
  ident: b0005
  article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
  publication-title: N. Engl. J. Med.
– reference: F. Barbaro, F. Della Rocca, A. Padoan, A. Aita, V. Cianci, D. Basso, A. Cattelan, D. Donato, M. Plebani, L. Dall’Olmo, A longitudinal study of healthcare workers’ surveillance during the ongoing COVID-19 Epidemics in Italy: is SARS-CoV-2 still a threat for the Health-care System? MedRxiv (2021) 2021.02.23.21249481, doi: 10.1101/2021.02.23.21249481.
– volume: 9
  start-page: 3989
  year: 2020
  ident: b0055
  article-title: Characterization of a Pan-immunoglobulin assay quantifying antibodies directed against the receptor binding domain of the SARS-CoV-2 S1-subunit of the spike protein: a population-based study
  publication-title: J. Clin. Med.
– volume: 383
  start-page: 2439
  year: 2020
  end-page: 2450
  ident: b0025
  article-title: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
  publication-title: N. Engl. J. Med.
– reference: A. Padoan, F. Bonfante, C. Cosma, C. Di Chiara, L. Sciacovelli, M. Pagliari, A. Bortolami, P. Costenaro, G. Musso, D. Basso, C. Giaquinto, M. Plebani, Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers, Clin. Chem. Lab. Med. (2021) (accepted for pubblication on April 1st, 2021).
– volume: 61
  year: 2020
  ident: b0060
  article-title: SARS-CoV-2 antibody-based SURVEILLANCE: new light in the SHADOW
  publication-title: EBioMedicine.
– volume: 509
  start-page: 1
  year: 2020
  ident: 10.1016/j.cca.2021.04.006_b0030
  article-title: Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays?
  publication-title: Clin. Chim. Acta.
  doi: 10.1016/j.cca.2020.05.050
– ident: 10.1016/j.cca.2021.04.006_b0040
  doi: 10.1101/2021.02.23.21249481
– volume: 368
  start-page: 489
  year: 2020
  ident: 10.1016/j.cca.2021.04.006_b0065
  article-title: Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)
  publication-title: Science (80)
  doi: 10.1126/science.abb3221
– volume: 26
  start-page: 1033
  year: 2020
  ident: 10.1016/j.cca.2021.04.006_b0035
  article-title: A serological assay to detect SARS-CoV-2 seroconversion in humans
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0913-5
– ident: 10.1016/j.cca.2021.04.006_b0075
  doi: 10.1056/NEJMc2101667
– volume: 384
  start-page: 403
  year: 2021
  ident: 10.1016/j.cca.2021.04.006_b0070
  article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2035389
– ident: 10.1016/j.cca.2021.04.006_b0095
  doi: 10.1515/cclm-2021-0023
– year: 2021
  ident: 10.1016/j.cca.2021.04.006_b0090
  article-title: Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination
  publication-title: JAMA
  doi: 10.1001/jama.2021.4388
– volume: 9
  start-page: 3989
  year: 2020
  ident: 10.1016/j.cca.2021.04.006_b0055
  article-title: Characterization of a Pan-immunoglobulin assay quantifying antibodies directed against the receptor binding domain of the SARS-CoV-2 S1-subunit of the spike protein: a population-based study
  publication-title: J. Clin. Med.
  doi: 10.3390/jcm9123989
– ident: 10.1016/j.cca.2021.04.006_b0085
  doi: 10.1016/S0140-6736(21)00501-8
– volume: 383
  start-page: 2603
  year: 2020
  ident: 10.1016/j.cca.2021.04.006_b0005
  article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2034577
– ident: 10.1016/j.cca.2021.04.006_b0020
– ident: 10.1016/j.cca.2021.04.006_b0045
  doi: 10.1101/2021.03.10.21253260
– volume: 27
  start-page: 279
  year: 2021
  ident: 10.1016/j.cca.2021.04.006_b0010
  article-title: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-01179-4
– volume: 383
  start-page: 2427
  year: 2020
  ident: 10.1016/j.cca.2021.04.006_b0015
  article-title: Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2028436
– volume: 383
  start-page: 2439
  year: 2020
  ident: 10.1016/j.cca.2021.04.006_b0025
  article-title: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2027906
– volume: 137
  year: 2021
  ident: 10.1016/j.cca.2021.04.006_b0050
  article-title: Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain
  publication-title: J. Clin. Virol.
  doi: 10.1016/j.jcv.2021.104784
– volume: 6736
  start-page: 10
  year: 2021
  ident: 10.1016/j.cca.2021.04.006_b0080
  article-title: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
  publication-title: Lancet
– volume: 61
  year: 2020
  ident: 10.1016/j.cca.2021.04.006_b0060
  article-title: SARS-CoV-2 antibody-based SURVEILLANCE: new light in the SHADOW
  publication-title: EBioMedicine.
  doi: 10.1016/j.ebiom.2020.103087
SSID ssj0004061
Score 2.572793
Snippet •Immune-induced vaccination has been suggested as a key global strategy for SARS-CoV-2.•Previous-natural infection subjects presented higher value of...
Vaccine-induced population immunity is a key global strategy to control coronavirus disease 2019 (COVID-19). The rapid implementation and availability of...
SourceID pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 60
SubjectTerms Antibody
BNT162b2
COVID-19
Immunoassays
Immunological response
SARS-CoV-2 vaccine
Serology
Title Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers
URI https://dx.doi.org/10.1016/j.cca.2021.04.006
https://www.ncbi.nlm.nih.gov/pubmed/33857476
https://www.proquest.com/docview/2514598060
https://pubmed.ncbi.nlm.nih.gov/PMC8056941
Volume 519
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB61Wwm4ICiv5VEZiRNSqJ3YsX1cVlQLqHtqpd4sxw81CCXVNj3Agd_OePOABdQDhySKnZFsjz3zTTyeAXgTSyHyMvqM6lBm3DqWWSpjJrlHsFxwKUM6jXy6Llfn_NOFuNiD5XgWJrlVDrK_l-lbaT2UHA-jeXxV1-mML03JD1MErPQ3Re7DQY7aXs3gYPHx82r963gkLdmYUC0RjJubWzcv7AFaiTnbBjxNeY_-rZ7-hp9_elH-ppZOHsD9AU-SRd_kh7AXmkO4uxzTuB3CndNh9_wRxEXT1VXrv5FN7xkbSNeSWCMAJLbx5DoZx574FivaSN6vz1iZVzmpG2JJyqS76VK5m2I8fw-eXE4OZCT5eCGafAznJx_OlqtsyLOQOcFkh2I4Mq-09SzkmlaWR1mpqgja0ehxfUqLfbS6YC5QqxAf5F4VzhaaC4eXLJ7ArGmb8AwIAgquUwhAVHo8CFcFvDl8qDIIpsIc6Di8xg1ByFMujK9m9Db7YpAjJnHEUG6QI3N4O5Fc9RE4bvuYjzwzO9PIoIa4jez1yF-D7El7JrYJ7c21QfjHhVa0pHN42vN7agVa9wKtMaSWOzNh-iCF7t6taerLbQhvhbhTc_b8_5r7Au6lt94P8SXMus1NeIXYqKuOYP_dD3Y0rICfUEcNfQ
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7SDTS9lDZ9bZ8q9FQwkWzZso_bpWHTZPe0gdyErAdxKXbYOIfm12dm_Wi3LTn0YBv0AEkjzXxjzQPgU8jSNM6Ci3jhs0gaKyLDVYiUdAiWE6mUJ2_k5SpbnMtvF-nFHswHXxgyq-x5f8fTt9y6LznqV_PoqqrIx5dT8kOKgEV_U9QD2JeU1HoC-7OT08Xql3skz8SQUI06DJebWzMvnAFqibHYBjylvEf_Fk9_w88_rSh_E0vHT-BxjyfZrBvyU9jz9SEczIc0bofwcNnfnj-DMKvbqmzcT7bpLGM9axsWKgSAzNSOXZNy7JhrsKIJ7MtqLbK4jFlVM8Mok-6mpXI7xni-9Y5djgZkjGy8EE0-h_Pjr-v5IurzLEQ2FapFNhyEywvjhI8LXhoZVJmXiS8sDw7PpzI4R1MkwnpucsQHscsTa5JCphYflbyASd3U_hUwBBSyoBCAKPSkT23p8WXxk2c-FbmfAh-WV9s-CDnlwvihB2uz7xopookimkuNFJnC57HLVReB477GcqCZ3tlGGiXEfd0-DvTVSB66MzG1b26uNcI_mRY5z_gUXnb0HkeB2n2K2hj2Vjs7YWxAobt3a-rqchvCO0fcWUjx-v-G-wEOFuvlmT47WZ2-gUdU09kkvoVJu7nx7xAnteX7_hzcAae9D2M
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibody+response+to+first+and+second+dose+of+BNT162b2+in+a+cohort+of+characterized+healthcare+workers&rft.jtitle=Clinica+chimica+acta&rft.au=Padoan%2C+Andrea&rft.au=Dall%27Olmo%2C+Luigi&rft.au=Rocca%2C+Foscarina+della&rft.au=Barbaro%2C+Francesco&rft.date=2021-08-01&rft.pub=Elsevier+B.V&rft.issn=0009-8981&rft.eissn=1873-3492&rft.volume=519&rft.spage=60&rft.epage=63&rft_id=info:doi/10.1016%2Fj.cca.2021.04.006&rft_id=info%3Apmid%2F33857476&rft.externalDocID=PMC8056941
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-8981&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-8981&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-8981&client=summon